WO2018066651A1 - 眼科用製品及び粘度低下抑制方法 - Google Patents
眼科用製品及び粘度低下抑制方法 Download PDFInfo
- Publication number
- WO2018066651A1 WO2018066651A1 PCT/JP2017/036293 JP2017036293W WO2018066651A1 WO 2018066651 A1 WO2018066651 A1 WO 2018066651A1 JP 2017036293 W JP2017036293 W JP 2017036293W WO 2018066651 A1 WO2018066651 A1 WO 2018066651A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- enclosure
- ophthalmic composition
- container
- vitamin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
- Y02W90/00—Enabling technologies or technologies with a potential or indirect contribution to greenhouse gas [GHG] emissions mitigation
- Y02W90/10—Bio-packaging, e.g. packing containers made from renewable resources or bio-plastics
Definitions
- the present invention relates to an ophthalmic product in which a decrease in viscosity of a water-soluble polymer compound is suppressed.
- a method in which a thickening agent such as a polymer compound is blended in order to improve effectiveness and maintain a refreshing feeling, thereby increasing drug retention on the ocular surface.
- the improvement in retention of the active ingredient on the ocular surface is considered to be particularly beneficial for active ingredients that act on corneal epithelial cells on the ocular surface such as vitamin A.
- a refreshing agent such as menthol is used.
- a refreshing component such as vitamin A and menthol is a fat-soluble component, a surfactant is often blended at the same time in order to blend these components into an aqueous eye drop.
- a method of blending vegetable oil such as sesame oil (Patent Document 1: Japanese Patent Laid-Open No. 2005-206598) or a method of blending castor oil (Patent Document 2: Japanese Patent Laid-Open No. 2005) -206599), and a method of adding mannitol or glycerin (Patent Document 3, Japanese Patent Laid-Open No. 11-71478) is known.
- the decrease in viscosity of the ophthalmic composition blended with the polymer compound is caused by the influence of various blending components, and a surfactant used when blending fat-soluble components such as vitamin A and menthol was added. At that time, a decrease in viscosity is particularly likely to occur, and the above-described method was not sufficient in suppressing the decrease in viscosity.
- the viscosity of the ophthalmic composition greatly contributes to improving the effectiveness of the drug and the sustainability of the refreshing agent, and also greatly affects the feeling of use resulting from the viscosity. For example, a viscosity that is too high is sticky or sticky, after use. There is a possibility of causing blurring of the field of view. Maintaining the design viscosity of the formulation without changing it is very important in terms of effectiveness and usability in maintaining the quality of the ophthalmic composition. Such a high viscosity stabilization method. Was desired.
- an ophthalmic composition containing a polymer compound containing a fat-soluble component such as vitamin A and a surfactant is likely to cause a decrease in viscosity over time, and polyoxyethylene cured castor as a surfactant. It has been found that this is particularly remarkable when oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil or polyethylene glycol monostearate is used. Therefore, it aims at providing the technique which suppresses such a viscosity fall.
- the present inventors have formulated specific components and used specific packaging means in an ophthalmic composition containing a polymer compound, a surfactant, and a fat-soluble component.
- a high viscosity reduction suppressing effect is exhibited.
- the ophthalmic composition provided by the present invention exhibits a high retention during instillation and is excellent in a moist feeling sustaining effect.
- the present invention provides the following. [1].
- A a water-soluble polymer compound
- B one or more surfactants selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil and polyethylene glycol monostearate
- C one or more components selected from vitamin A, vitamin E, dibutylhydroxytoluene and a refreshing agent
- D one or more components selected from the group consisting of (D-1) and (D-2) below (D-1) trometamol, propylene glycol (D-2) ethylenediamineacetic acid derivative, ethylenediamineacetic acid derivative salt, tetrahydrozoline hydrochloride, epsilon aminocaproic acid, allantoin, glycyrrhizic acid, glycyrrhizinate, chlorpheniramine maleate, pyridoxine hydrochloride, Contains panthenol, chondroitin sulfate, a water
- the ophthalmic composition includes: (D) (D-1) and (D-2) below (D-1) trometamol, propylene glycol (D-2) ethylenediamineacetic acid derivative, ethylenediamineacetic acid derivative salt, tetrahydrozoline hydrochloride, epsilon
- A a water-soluble polymer compound
- B one or more surfactants selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil and polyethylene glycol monostearate
- C In an ophthalmic composition containing one or more fat-soluble components selected from vitamin A, vitamin E, dibutylhydroxytoluene and a refreshing agent, A container filled with the ophthalmic composition; and an enclosure for packaging the container; (1) injection of an inert gas into the enclosure; (2) bundling of an oxygen absorbent into the enclosure; While using any one or more means of (3) a container having oxygen absorption capacity or (4) an enclosure having oxygen absorption capacity, (D) (D-1) and (D-2) below (D-1) trometamol, propylene glycol (D-2) ethylenediamineacetic acid derivative, ethylenediamineacetic acid derivative salt, tetrahydrozoline hydrochloride, epsilon aminocaproic acid,
- a high viscosity reduction inhibitory effect can be obtained in a composition containing a polymer compound, a surfactant and a fat-soluble component.
- water-soluble polymer compounds include cellulose polymer compounds such as hydroxypropylmethylcellulose (hypromellose), methylcellulose, and hydroxyethylcellulose; polyvinyl polymer compounds such as polyvinylpyrrolidone (povidone) and polyvinyl alcohol; hyaluronic acid and salts thereof; carboxy A vinyl polymer etc. are mentioned, It can use individually by 1 type or in combination of 2 or more types. By blending such components, it is possible to impart viscosity to the composition, improve the retention of the blended active ingredients on the ocular surface, and prevent drying of the ocular surface by retaining on the ocular surface. it can.
- cellulose polymer compounds such as hydroxypropylmethylcellulose (hypromellose), methylcellulose, and hydroxyethylcellulose
- polyvinyl polymer compounds such as polyvinylpyrrolidone (povidone) and polyvinyl alcohol
- hyaluronic acid and salts thereof carboxy A vinyl polymer etc.
- hydroxypropylmethylcellulose methylcellulose, hydroxyethylcellulose, polyvinylpyrrolidone, carboxyvinyl polymer, hyaluronic acid and salts thereof are preferable, and hydroxypropylmethylcellulose is more preferable.
- the water solubility of the water-soluble polymer compound is a polymer that can be dissolved in an aqueous solution, and its weight average molecular weight is preferably 5,000 to 5,000,000, more preferably 10,000 to 2,500,000. .
- the measurement of a weight average molecular weight can be calculated
- the compounding amount of the component (A) is preferably 0.01 to 10% (W / V% (mass / volume%, g / 100 mL or less)) in the composition, and more preferably 0.05 to 3%.
- the content is preferably 0.05 to 5%, more preferably 0.1 to 3%, still more preferably 0.1 to 0.5%.
- methylcellulose is blended, it is preferably 0.05 to 5% in the composition, more preferably 0.1 to 3%, and still more preferably 0.1 to 1%.
- the content is preferably 0.05 to 5%, more preferably 0.1 to 3%, and still more preferably 0.1 to 1%.
- the content is preferably 0.01 to 10%, more preferably 0.05 to 5%, and still more preferably 0.05 to 3%.
- the content is preferably 0.01 to 5%, more preferably 0.05 to 3%, still more preferably 0.1 to 1%.
- the content is preferably 0.01 to 3%, more preferably 0.01 to 1%, still more preferably 0.02 to 1%.
- the component (B) is one or more surfactants selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil, and polyethylene glycol monostearate.
- polyoxyethylene hydrogenated castor oil As polyoxyethylene hydrogenated castor oil (POE hydrogenated castor oil), several types are known depending on the average number of moles of ethylene oxide added to the hydrogenated castor oil. Specifically, polyoxyethylene hydrogenated castor oil 5 (the numerical value is the average number of moles of ethylene oxide added, the same applies hereinafter), polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 20, polyoxyethylene hydrogenated castor oil 30, Examples include polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene hydrogenated castor oil 80, and polyoxyethylene hydrogenated castor oil 100. These polyoxyethylene hydrogenated castor oils can be used singly or in appropriate combination of two or more. From the viewpoint of safety, it is preferable to use polyoxyethylene hydrogenated castor oil 40 and polyoxyethylene hydrogenated castor oil 60.
- monolauric acid POE (20) sorbitan As polyoxyethylene sorbitan fatty acid ester, monolauric acid POE (20) sorbitan (POE is polyoxyethylene, the numerical value is the average added mole number of ethylene oxide, the same applies hereinafter), monopalmitic acid POE (20) sorbitan (polysorbate 40), Examples include monostearic acid POE (20) sorbitan (polysorbate 60), tristearic acid POE (20) sorbitan (polysorbate 65), monooleic acid POE (20) sorbitan (polysorbate 80), and the like. The above can be used in appropriate combination. Among these, monooleic acid POE (20) sorbitan (polysorbate 80) is preferable.
- polyoxyethylene castor oil polyoxyethylene castor oil having an average added mole number of ethylene oxide in the range of 3 to 60 mol is preferable.
- polyoxyethylene castor oil 3 the numerical value is that of ethylene oxide).
- Average number of moles added the same applies hereinafter
- polyoxyethylene castor oil 10 polyoxyethylene castor oil 20
- polyoxyethylene castor oil 35 polyoxyethylene castor oil 40
- polyoxyethylene castor oil 50 polyoxyethylene castor oil 60 Is mentioned.
- the number of moles of ethylene oxide added is more preferably 10 to 50, still more preferably 20 to 40.
- Polyoxyethylene castor oil and polyoxyethylene hydrogenated castor oil are different components.
- Polyethylene glycol monostearate (polyethylene glycol monostearate) is polyoxyl stearate 10 (polyethylene glycol monostearate (10), the value is the average number of moles of ethylene glycol added, the same applies hereinafter), polyoxyl stearate 40, stearin Acid polyoxyl 45, stearic acid polyoxyl 55, etc. are mentioned, and among them, stearic acid polyoxyl 40 is preferable.
- surfactants may be used alone or in combination of two or more.
- polyoxyethylene hydrogenated castor oil and polyoxyethylene sorbitan fatty acid ester can be used in appropriate combination.
- the blending amount of the component (B) is preferably 0.01 to 7%, more preferably 0.05 to 5%, still more preferably 0.1 to 3% in the composition as the total amount of the component (B).
- the component (C) and the like can be blended more stably.
- the upper limit or less there is no fear of irritation due to the component (B).
- Component (C) It is 1 or more types of components chosen from vitamin A, vitamin E, dibutylhydroxytoluene, and a refreshing agent, This fat-soluble component can be used individually by 1 type or in combination of 2 or more types.
- Vitamin A has a corneal wound healing effect and the like, and in addition to vitamin A itself, vitamin A-containing mixtures such as vitamin A oil, vitamin A derivatives such as vitamin A fatty acid esters and the like can be mentioned. Specific examples include retinol palmitate, retinol acetate, retinol, retinoic acid, and retinoid. Of these, retinol palmitate is preferred.
- the blending amount is preferably 5,000 to 500,000 international units (IU) in 100 mL of the ophthalmic composition, more preferably 10,000 to 100,000 international units (IU), 30 More preferably, 5,000-75,000 international units (IU).
- IU international units
- a corneal wound healing effect due to vitamin A can be expected at a lower limit value or more, and vitamin A stability can be further obtained at an upper limit value or less.
- vitamin E examples include tocopherol acetate (dl- ⁇ -tocopherol acetate, d- ⁇ -tocopherol acetate (vitamin E)), tocopherol succinate, and derivatives thereof. Of these, d- ⁇ -tocopherol acetate is preferred.
- the blending amount is preferably 0.005 to 0.5%, more preferably 0.01 to 0.1% in the ophthalmic composition.
- the effect and stability can be further improved within the above range.
- the blending amount is preferably 0.001 to 0.05%, more preferably 0.003 to 0.01% in the ophthalmic composition.
- the effect and stability can be further improved within the above range.
- Refreshing agents include menthol, camphor, cool mint, geraniol, mint water, borneol, eucalyptus oil, fennel oil, rose oil, bergamot oil, peppermint oil, spearmint oil, linalool, anethole, eugenol, cineol, N-ethyl- and p-menthane-carboxamide.
- These cooling agents can be used singly or in appropriate combination of two or more.
- menthol is preferable, and when combining two or more kinds, it is preferable to combine menthol and another cooling agent.
- the blending amount is preferably 0.001 to 0.5%, more preferably 0.005 to 0.3% in the ophthalmic composition. Within the above range, an effect and a good refreshing feeling upon instillation can be obtained.
- [(D) component] (D) One or more selected from the group consisting of (D-1) and (D-2) below. (D) By mix
- ethylenediamineacetic acid derivatives or salts thereof examples include edetic acid (ethylenediaminetetraacetic acid), ethylenediaminediacetic acid, diethylenetriaminepentaacetic acid, N- (2-hydroxyethyl) ethylenediaminetriacetic acid, sodium edetate (ethylenediaminetetraacetic acid sodium), ethylenediamine Disodium tetraacetate), and hydrates thereof.
- edetic acid ethylenediaminetetraacetic acid
- ethylenediaminediacetic acid diethylenetriaminepentaacetic acid
- N- (2-hydroxyethyl) ethylenediaminetriacetic acid N- (2-hydroxyethyl) ethylenediaminetriacetic acid
- sodium edetate ethylenediaminetetraacetic acid sodium
- ethylenediamine Disodium tetraacetate examples include hydrates thereof.
- Examples of glycyrrhizic acid or a salt thereof include glycyrrhizic acid, dipotassium glycyrrhizinate, disodium glycyrrhizinate, diammonium glycyrrhizinate, and the like.
- Examples of chondroitin sulfate or a salt thereof include chondroitin sulfate, chondroitin polysulfate, sodium chondroitin sulfate, and the like.
- Aspartic acid or a salt thereof includes, for example, sodium L-aspartate, potassium L-aspartate, magnesium L-aspartate, calcium L-aspartate, magnesium L-aspartate and potassium (L-aspartate and L- And an equivalent mixture with potassium aspartate).
- (D-1) component trometamol and propylene glycol are preferred
- (D-2) component is allantoin, panthenol, chloro. Phenylamine maleate and pyridoxine hydrochloride are preferred.
- two or more types it is preferably one or more types from the (D-1) group and one or more types from the (D-2) group.
- the blending amount of component (D) is preferably 0.001 to 10%, more preferably 0.005 to 5%, and still more preferably 0.01 to 3% in the ophthalmic composition. By setting it as this range, the viscosity fall by using together the viscosity reduction component by using together said (A) and (B) component can be suppressed more.
- Trometamol is 0.01 to 10%, more preferably 0.1 to 5%.
- Propylene glycol is 0.01 to 10%, more preferably 0.1 to 5%.
- the ethylenediamineacetic acid derivative or a salt thereof is 0.001 to 2%, more preferably 0.01 to 1.5%.
- Tetrahydrozoline hydrochloride is 0.001 to 2%, more preferably 0.01 to 1%.
- Epsilon aminocaproic acid is 0.01 to 10%, more preferably 0.1 to 5%.
- Allantoin is 0.001 to 5%, more preferably 0.01 to 1%.
- Glycyrrhizic acid or a salt thereof is 0.001 to 5%, more preferably 0.01 to 1%.
- Chlorpheniramine maleate is 0.001-1%, more preferably 0.003-0.1%.
- Pyridoxine hydrochloride is 0.001 to 2%, more preferably 0.01 to 1%.
- Panthenol is 0.001 to 2%, more preferably 0.01 to 1%.
- Chondroitin sulfate or a salt thereof is 0.001 to 5%, more preferably 0.01 to 2%.
- Sodium chloride is 0.01 to 2%, more preferably 0.05 to 1%.
- Neostigmine methyl sulfate is 0.0001 to 1%, more preferably 0.0005 to 0.1%.
- Zinc sulfate is 0.001 to 2%, more preferably 0.025 to 1%.
- Flavin adenine dinucleotide sodium is 0.0001 to 1%, more preferably 0.005 to 0.1%.
- Cyanocobalamin is 0.001-1%, more preferably 0.002-0.1%.
- Aspartic acid or a salt thereof is 0.01 to 5%, more preferably 0.05 to 2%.
- Aminoethylsulfonic acid is 0.01 to 5%, more preferably 0.05 to 2%.
- ophthalmic composition of the present invention various components used in the ophthalmic composition can be blended as necessary within a range that does not impair the effects of the present invention.
- Preferred compounding ingredients include drugs, buffers, stabilizers, tonicity agents, antioxidants, preservatives and the like. These can be used individually by 1 type or in combination of 2 or more types, and can mix
- Examples of the drug include a decongestant component other than the component (D), an eye muscle modulator component, an anti-inflammatory component or an astringent component, an antihistamine component or an antiallergic component, vitamins, amino acids, antibacterial component Or a bactericide component, saccharides, polysaccharides other than (A) component or derivatives thereof, polyhydric alcohol, local anesthetic components, steroid components, glaucoma treatment components, cataract treatment components, mydriasis components and the like. Specific examples are shown below.
- Decongestant ⁇ -adrenergic agonist, for example, imidazoline derivatives (naphazoline, tetrahydrozoline, etc.), ⁇ -phenylethylamine derivatives (phenylephrine, epinephrine, ephedrine, methylephedrine, etc.), and their pharmaceutically or physiologically acceptable Salts (for example, inorganic acid salts such as naphazoline hydrochloride, naphazoline nitrate, tetrahydrozoline nitrate, phenylephrine hydrochloride, epinephrine hydrochloride, ephedrine hydrochloride, and methylephedrine hydrochloride; organic acid salts such as epinephrine hydrogen tartrate) and the like.
- imidazoline derivatives naphazoline, tetrahydrozoline, etc.
- ⁇ -phenylethylamine derivatives phenyleph
- O Eye muscle modulator component cholinesterase inhibitor having an active center similar to acetylcholine, tropicamide, atropine sulfate and the like.
- Anti-inflammatory or astringent components pranoprofen, celecoxib, rofecoxib, indomethacin, diclofenac, diclofenac sodium, piroxicam, meloxicam, aspirin, mefenamic acid, indomethacin farnesyl, acemetacin, ibuprofen, thiaprofenic acid, loxoprofen sodium, zinc thiaramide hydrochloride
- salts for example, zinc chloride and zinc lactate
- lysozyme lysozyme hydrochloride
- methyl salicylate sodium azulene sulfonate
- berberine chloride berberine sulfate and the like.
- Antihistamine component or antiallergic component for example, ketotifen, acitazanolast, diphenhydramine, levocabastine, cromoglycic acid, tranilast, ibudilast, amlexanox, pemirolast and pharmaceutically or physiologically acceptable salts thereof (diphenhydramine hydrochloride, Ketotifen fumarate, sodium cromoglycate, etc.).
- Vitamins examples include ascorbic acid, thiamine, niacin, vitamin D, vitamin K, and the like.
- Amino acids for example, leucine, isoleucine, valine, methionine, threonine, alanine, phenylalanine, tryptophan, lysine, glycine, serine, proline, tyrosine, cysteine, histidine, ornithine, hydroxyproline, hydroxylysine, glycylglycine, ⁇ -amino
- Examples include butyric acid and glutamic acid.
- Antibacterial component or bactericidal component sulfonamides (for example, sulfamethoxazole, sulfisoxazole, sulfisomidine and pharmacologically acceptable salts (sulfamethoxazole sodium, sulfisomidine sodium, etc.) ), Etc.), acrinol, alkylpolyaminoethylglycine, new quinolone (lomefloxacin, levofloxacin, ciprofloxacin, ofloxacin, norfloxacin, ciprofloxacin hydrochloride, etc.), ⁇ -lactam antibacterial (sulbenicillin, cefmenoxime, etc.), aminoglycoside Antibacterial agents (kanamycin, gentamicin, tobramycin, sisomycin, dibekacin, bekanamycin, micronomycin, etc.), tetracycline antibacterial agents (oxytetracycline
- antiviral drugs idoxuridine, acyclovir, adenine arabinoside, ganciclovir, foscarnet, valacyclovir, trifluorothymidine, cidofovir, carbocyclic oxetanocin G, etc.
- antifungal drugs pimaricin, fluconazole, itraconazole, And miconazole, flucytosine, amphotericin B, etc.
- saccharide examples include lactulose, raffinose, pullulan, glucose, maltose, trehalose, sucrose, cyclodextrin, xylitol, mannitol, sorbitol and the like.
- Polysaccharides or derivatives thereof gum arabic, karaya gum, xanthan gum, carob gum, guar gum, guaiac gum, quince seed, dalman gum, tragacanth, benzoin gum, locust bean gum, casein, agar, alginic acid, dextrin, dextran, carrageenan, gelatin, collagen, Examples include pectin, starch, polygalacturonic acid (alginic acid), chitin and derivatives thereof, chitosan and derivatives thereof, and elastin.
- Polyhydric alcohol glycerin, butylene glycol, polyethylene glycol and the like.
- Local anesthetic ingredients chlorobutanol, lidocaine, oxybuprocaine, dipcaine, procaine, ethyl aminobenzoate, meprilucaine, mepivacaine, bupivacaine, cocaine and their salts (lidocaine hydrochloride, oxybuprocaine hydrochloride, etc.) .
- Steroid component Hydrocortisone, prednisolone, cortisol, methylprednisolone, triamcinolone, parameterzone, betamethasone and their salts.
- Glaucoma treatment ingredients Distigmine bromide, timolol maleate, carteolol hydrochloride, betaxolol hydrochloride, latanoprost, isopropylunoprostone, dipivefrine hydrochloride, apraclonidine hydrochloride, pilocarpine hydrochloride, carbachol, dorzolamide hydrochloride, acetazolamide, metazolamide Etc.
- Cataract treatment ingredients pirenoxine, glutathione, salivary gland hormone, thiopronin, Dihydro azapentacene disulfonate and salts thereof (for example, Sodium 5, 12-dihydro azapentacene disulfonate) and the like.
- Mydriatic component cyclopentrate hydrochloride, tropicamide and the like.
- an effective appropriate amount of each drug can be selected as the compounding amount, but 0.0001 in the ophthalmic composition from the viewpoint of eye irritation, composition stability, and the like. It is preferably in the range of -5%, and preferably in the range of 0.001-5%.
- the buffer examples include citric acid, sodium citrate, boric acid, borax, phosphoric acid, sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, acetic acid, sodium acetate, glacial acetic acid, sodium carbonate. Sodium bicarbonate and sodium sulfite are preferably used.
- the blending amount is preferably in the range of 0.003 to 4% in the composition.
- the stabilizer examples include ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin and the like.
- the blending amount is preferably in the range of 0.003 to 2% in the composition.
- the isotonic agent examples include potassium chloride, calcium chloride, magnesium chloride, potassium acetate, sodium acetate, sodium carbonate, magnesium sulfate, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium hydrogen sulfite and the like.
- the blending amount is preferably in the range of 0.001 to 3% in the composition.
- antioxidants examples include butylhydroxyanisole (BHA), hydroquinone, propyl gallate, sodium bisulfite and the like.
- BHA butylhydroxyanisole
- hydroquinone hydroquinone
- propyl gallate sodium bisulfite
- the blending amount is preferably in the range of 0.001 to 1% in the composition.
- preservatives include parabens such as benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, sorbic acid, potassium sorbate, chlorobutanol, paraoxybenzoate, polydronium chloride, alkyldiaminoethylglycine hydrochloride, sodium benzoate, Examples include polyhexamethylene biguanide.
- the blending amount thereof is preferably in the range of 0.0001 to 0.5% in the composition, and more preferably in the range of 0.001 to 0.5%.
- vitamin A having a corneal wound healing effect or the like as the component (C) in order to further reduce irritation to the cornea and to make a safer composition, these preservatives are not added. Most preferred.
- the ophthalmic composition of the present invention can be produced by a known production method with the balance being water.
- each of the above components can be obtained by dissolving in sterilized purified water, water such as ion exchange water, or a mixed solvent with water.
- the pH is adjusted after pouring into a high-temperature (70 to 95 ° C) aqueous solution in which other aqueous components are dissolved
- it can be obtained by adjusting the osmotic pressure and the like appropriately with a pH adjusting agent and an isotonizing agent as required.
- pH regulators include hydrochloric acid, sulfuric acid, phosphoric acid, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide and the like.
- the pH (20 ° C.) of the ophthalmic composition of the present invention is preferably 3.5 to 8.0, more preferably 4.5 to 7.7, and still more preferably 5.5 to 7.5. If the pH is too low or too high, the feeling of irritation can be strong.
- the pH is measured at 20 ° C. using a pH osmometer (HSMO-1, Toa DKK Corporation).
- As the pH adjuster sodium hydroxide, potassium hydroxide, hydrochloric acid and the like are preferable.
- the ophthalmic composition of the present invention is preferably a liquid, and the viscosity at 20 ° C. is preferably 1 to 400 mPa ⁇ s, more preferably 1 to 100 mPa ⁇ s, still more preferably 1 to 60 mPa ⁇ s, and more preferably 1 to 30 mPa ⁇ s. Particularly preferred.
- the viscosity is measured using a B-type viscometer.
- the ophthalmic composition of the present invention can be used as a preparation used for contact lens care in addition to pharmaceuticals and quasi drugs applied to the eye.
- eye drops including eye drops for general use, artificial tears, eye drops that can be instilled while wearing contact lenses, etc.
- eye wash eye wash to be used for naked eyes, eye wash that can be washed while wearing contact lenses
- Contact lens removal solution contact lens removal solution
- contact lens care solution contact lens disinfectant, contact lens preservative, contact lens cleaning agent, contact lens
- eye drops, eye washes, and contact lens mounting liquids are suitable preparation forms of the ophthalmic composition of the present invention, and eye drops are particularly preferable.
- all contact lenses including a hard contact lens and a soft contact lens are included.
- the present invention is an ophthalmic product comprising an ophthalmic composition, a container filled with the ophthalmic composition, and an enclosure for packaging the container, wherein the oxygen concentration in the ophthalmic composition is reduced.
- Means include (1) injecting inert gas into the enclosure, (2) bundling of oxygen absorbent into the enclosure, (3) container having oxygen absorption capacity, or (4) enclosure having oxygen absorption capacity. Etc. By such means, a decrease in viscosity due to the combined use of the above components (A) and (B) can be further suppressed.
- the enclosure is preferably capable of sealing the container.
- the container is preferably a plastic container, and materials such as polyethylene, polyethylene terephthalate, polypropylene, polybutylene, polycarbonate, polyarylate, vinyl chloride, or a composite of these materials can be used. Polyethylene terephthalate is particularly preferable.
- the oxygen permeability coefficient of the container is preferably 10 cc / m 2 ⁇ 24 hr ⁇ atm or more.
- the amount of the ophthalmic composition in the product can be appropriately selected depending on the product and its method of use. For example, in the case of eye drops, 2 to 20 mL is preferable, and 5 to 20 mL is more preferable.
- the capacity of the container is preferably appropriately selected according to the amount of the ophthalmic composition to be filled, and is preferably 100 to 150% with respect to the amount of the ophthalmic composition to be filled.
- the eye drop is not particularly limited, and may be a multi-dose eye drop or a disposable eye drop.
- the envelope examples include polyethylene, polyethylene terephthalate, polypropylene, polybutylene, polycarbonate, polyester, nylon, cellophane, polyvinyl chloride film, aluminum foil, polyvinyl alcohol / polyamide film deposited with aluminum, and polyvinylidene chloride. Examples thereof include composites such as films and laminate films, and multilayer films.
- the oxygen permeability coefficient of the envelope is preferably 10 cc / m 2 ⁇ 24 hr ⁇ atm or less (that is, 0 to 10 cc / m 2 ⁇ 24 hr ⁇ atm).
- the inert gas includes nitrogen, helium, neon, argon, and the like. Of these, nitrogen gas is preferred.
- the concentration of the inert gas is preferably 50% by volume or more, more preferably 80% by volume or more, and still more preferably 90% by volume or more in the space volume formed between the enclosure and the plastic container.
- An upper limit is not specifically limited, It is 100 volume% or less. In order to achieve such a concentration, the space formed between the enclosure and the plastic container may be replaced with an inert gas.
- Container having oxygen absorbing ability Specifically, an oxyblock manufactured by Toyo Seikan Co., Ltd., an oxyvanish manufactured by Mitsubishi Gas Chemical Co., Ltd., or the like can be used.
- Oxycatch (registered trademark) ICA manufactured by Kyodo Printing Co., Ltd., Cryovac (registered trademark) OS film manufactured by Shield Air Co., Ltd., manufactured by Star Plastic Industry Co., Ltd. Histar O2, Noge Omega manufactured by Mitsubishi Gas Chemical Co., Ltd., Oxydec manufactured by Toyo Seikan Co., Ltd., and the like can be used.
- the present invention provides (A) a water-soluble polymer compound, (B) one or more surfactants selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil and polyethylene glycol monostearate, (C) an ophthalmic composition containing one or more fat-soluble components selected from vitamin A, vitamin E, dibutylhydroxytoluene and a refreshing agent, a container filled with the ophthalmic composition, and the container (1) Inert gas injection into the enclosure, (2) Enclosure of oxygen absorbent in the enclosure, (3) Container having oxygen absorption capacity, or (4) Oxygen absorption
- the ophthalmic composition includes: (D) (D-1) and (D-2) below (D-1) trometamol, propylene glycol (D-2) ethylenediamineacetic acid derivative, ethylenediamineacetic acid derivative salt, tetrahydrozoline hydrochloride, e
- the present invention provides (A) a water-soluble polymer compound, (B) one or more surfactants selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil and polyethylene glycol monostearate, (C) In an ophthalmic composition containing one or more fat-soluble components selected from vitamin A, vitamin E, dibutylhydroxytoluene and a refreshing agent, A container filled with the ophthalmic composition; and an enclosure for packaging the container; (1) injection of an inert gas into the enclosure; (2) bundling of an oxygen absorbent into the enclosure; While using any one or more means of (3) a container having oxygen absorption capacity or (4) an enclosure having oxygen absorption capacity, (D) (D-1) and (D-2) below (D-1) trometamol, propylene glycol (D-2) ethylenediamineacetic acid derivative, ethylenediamineacetic acid derivative salt, tetrahydrozoline hydrochloride, epsilon aminocaproic
- W / V% of a composition is g / 100mL.
- the ophthalmic composition having the composition shown in the following table is dissolved in the component (B) and then poured into a high temperature (70 to 95 ° C.) aqueous solution in which the other aqueous solution components are dissolved.
- a compositional ophthalmic composition was prepared.
- the obtained ophthalmic composition (15 mL) was filled into a polyethylene terephthalate eye drop container (16 mL), and then an oxygen absorbent (AGELESS: Z-20PK manufactured by Mitsubishi Gas Chemical Co., Ltd.) in a film package ( Enclosed body).
- the ophthalmic product filled with the ophthalmic composition having the composition shown in the following table in the container described in the present invention and packaged in the packaging form described in the present invention is suppressed in viscosity reduction over time, and maintains its effectiveness and refreshing feeling. It can be used as an eye drop having excellent properties and a long-lasting moist feeling.
- Formulation Examples 3, 5, 10 to 12 are suitable as eye drops for contacts that can be instilled even when a soft contact lens is worn.
- Hydroxypropyl methylcellulose Metroze 60SH-4000, JP, Shin-Etsu Chemical Co., Ltd., weight average molecular weight of about 300,000 (g / mol)
- Methylcellulose Metroles SM-4000, JP, Shin-Etsu Chemical Co., Ltd., weight average molecular weight of about 360,000 (g / mol)
- Hydroxyethyl cellulose HEC-CF-V, supplementary regulations, Sumitomo Seika Co., Ltd., weight average molecular weight of about 1 million (g / mol)
- Polyvinylpyrrolidone Kollidon 90F, JP, BASF Corporation, weight average molecular weight 1 million (g / mol)
- Carboxyvinyl polymer Carbopol (registered trademark) 971PNF, supplementary regulations, Lubrizol Corporation Sodium hyalur
- Dibutylhydroxytoluene Dibutylhydroxytoluene, supplementary regulations, Wako Pure Chemical Industries, Ltd.
- component (D) and other optional components various raw materials conforming to official standards (Japanese Pharmacopoeia, Japanese Pharmacopoeia Pharmaceutical Standards, Pharmaceutical Additive Standards, etc.) standards were used.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
[1].(A)水溶性高分子化合物、
(B)ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油及びモノステアリン酸ポリエチレングリコールから選ばれる1種又は2種以上の界面活性剤、
(C)ビタミンA、ビタミンE、ジブチルヒドロキシトルエン及び清涼化剤から選ばれる1種以上の成分、及び
(D)下記(D-1)及び(D-2)からなる群から選ばれる1種以上
(D-1)トロメタモール、プロピレングリコール
(D-2)エチレンジアミン酢酸誘導体、エチレンジアミン酢酸誘導体塩、塩酸テトラヒドロゾリン、イプシロンアミノカプロン酸、アラントイン、グリチルリチン酸、グリチルリチン酸塩、クロルフェニラミンマレイン酸塩、ピリドキシン塩酸塩、パンテノール、コンドロイチン硫酸、コンドロイチン硫酸塩、塩化ナトリウム、ネオスチグミンメチル硫酸塩、硫酸亜鉛、フラビンアデニンジヌクレオチドナトリウム、シアノコバラミン、アスパラギン酸、アスパラギン酸塩、アミノエチルスルホン酸
を含有する眼科用組成物と、この眼科用組成物が充填された容器と、この容器を包装する包囲体とを有する眼科用製品であって、
(1)包囲体内への不活性ガス注入、(2)包囲体内への酸素吸収剤の同梱、(3)酸素吸収能を有する容器又は(4)酸素吸収能を有する包囲体のいずれか1以上の手段を用いた眼科用製品。
[2].(D)成分が、(D-1)群から1種以上及び(D-2)群から1種以上である[1]記載の眼科用製品。
[3].(A)成分が、ヒドロキシプロピルメチルセルロース、メチルセルロース、ヒドロキシエチルセルロース、ポリビニルピロリドン、ポリビニルアルコール、カルボキシビニルポリマー、ヒアルロン酸及びその塩から選ばれる1種以上である[1]又は[2]記載の眼科用製品。
[4].(C)成分が、レチノールパルミチン酸エステル、酢酸d-α-トコフェロール、ジブチルヒドロキシトルエン及びメントールから選ばれる1種以上である[1]~[3]のいずれかに記載の眼科用製品。
[5].(A)水溶性高分子化合物、
(B)ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油及びモノステアリン酸ポリエチレングリコールから選ばれる1種又は2種以上の界面活性剤、
(C)ビタミンA、ビタミンE、ジブチルヒドロキシトルエン及び清涼化剤から選ばれる1種以上の脂溶性成分を含有する眼科用組成物と、この眼科用組成物が充填された容器と、この容器を包装する包囲体とを有し、(1)包囲体内への不活性ガス注入、(2)包囲体内への酸素吸収剤の同梱、(3)酸素吸収能を有する容器又は(4)酸素吸収能を有する包囲体のいずれか1以上の手段を用いた眼科用製品において、上記眼科用組成物に、
(D)下記(D-1)及び(D-2)
(D-1)トロメタモール、プロピレングリコール
(D-2)エチレンジアミン酢酸誘導体、エチレンジアミン酢酸誘導体塩、塩酸テトラヒドロゾリン、イプシロンアミノカプロン酸、アラントイン、グリチルリチン酸、グリチルリチン酸塩、クロルフェニラミンマレイン酸塩、ピリドキシン塩酸塩、パンテノール、コンドロイチン硫酸、コンドロイチン硫酸塩、塩化ナトリウム、ネオスチグミンメチル硫酸塩、硫酸亜鉛、フラビンアデニンジヌクレオチドナトリウム、シアノコバラミン、アスパラギン酸、アスパラギン酸塩、アミノエチルスルホン酸
からなる群から選ばれる1種以上を配合することを特徴とする、上記眼科用組成物の粘度低下抑制方法。
[6].(A)水溶性高分子化合物、
(B)ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油及びモノステアリン酸ポリエチレングリコールから選ばれる1種又は2種以上の界面活性剤、
(C)ビタミンA、ビタミンE、ジブチルヒドロキシトルエン及び清涼化剤から選ばれる1種以上の脂溶性成分を含有する眼科用組成物において、
この眼科用組成物が充填された容器と、この容器を包装する包囲体とを有し、(1)包囲体内への不活性ガス注入、(2)包囲体内への酸素吸収剤の同梱、(3)酸素吸収能を有する容器又は(4)酸素吸収能を有する包囲体のいずれか1以上の手段を用いると共に、上記眼科用組成物に、
(D)下記(D-1)及び(D-2)
(D-1)トロメタモール、プロピレングリコール
(D-2)エチレンジアミン酢酸誘導体、エチレンジアミン酢酸誘導体塩、塩酸テトラヒドロゾリン、イプシロンアミノカプロン酸、アラントイン、グリチルリチン酸、グリチルリチン酸塩、クロルフェニラミンマレイン酸塩、ピリドキシン塩酸塩、パンテノール、コンドロイチン硫酸、コンドロイチン硫酸塩、塩化ナトリウム、ネオスチグミンメチル硫酸塩、硫酸亜鉛、フラビンアデニンジヌクレオチドナトリウム、シアノコバラミン、アスパラギン酸、アスパラギン酸塩、アミノエチルスルホン酸
からなる群から選ばれる1種以上を配合することを特徴とする、上記眼科用組成物の粘度低下抑制方法。
[(A)成分]
水溶性高分子化合物としては、ヒドロキシプロピルメチルセルロース(ヒプロメロース)、メチルセルロース、ヒドロキシエチルセルロース等のセルロース系高分子化合物、ポリビニルピロリドン(ポビドン)、ポリビニルアルコール等のポリビニル系高分子化合物、ヒアルロン酸及びその塩、カルボキシビニルポリマー等が挙げられ、1種単独で又は2種以上を適宜組み合わせて用いることができる。このような成分を配合することで、組成物に粘度を付与し、配合された有効成分の眼表面での滞留性を向上し、眼表面に滞留することにより眼表面の乾燥を防止することができる。中でも、ヒドロキシプロピルメチルセルロース、メチルセルロース、ヒドロキシエチルセルロース、ポリビニルピロリドン、カルボキシビニルポリマー、ヒアルロン酸及びその塩が好ましく、ヒドロキシプロピルメチルセルロースがより好ましい。
(B)成分は、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油及びモノステアリン酸ポリエチレングリコールから選ばれる1種又は2種以上の界面活性剤である。
ビタミンA、ビタミンE、ジブチルヒドロキシトルエン及び清涼化剤から選ばれる1種以上の成分であり、この脂溶性成分を1種単独で又は2種以上を適宜組み合わせて用いることができる。ビタミンAには角膜創傷治癒効果等があり、ビタミンAそれ自体の他に、ビタミンA油等のビタミンA含有混合物、ビタミンA脂肪酸エステル等のビタミンA誘導体等が挙げられる。具体的には、レチノールパルミチン酸エステル、レチノール酢酸エステル、レチノール、レチノイン酸、レチノイド等が挙げられる。中でも、レチノールパルミチン酸エステルが好ましい。
(D)下記(D-1)及び(D-2)からなる群から選ばれる1種以上である。(D)成分の配合により、上記(A),(B)成分を併用することによる粘度低下を抑制することができる。
(D-1)トロメタモール、プロピレングリコール
(D-2)エチレンジアミン酢酸誘導体、エチレンジアミン酢酸誘導体塩、塩酸テトラヒドロゾリン、イプシロンアミノカプロン酸、アラントイン、グリチルリチン酸、グリチルリチン酸塩、クロルフェニラミンマレイン酸塩、ピリドキシン塩酸塩、パンテノール、コンドロイチン硫酸、コンドロイチン硫酸塩、塩化ナトリウム、ネオスチグミンメチル硫酸塩、硫酸亜鉛、フラビンアデニンジヌクレオチドナトリウム、シアノコバラミン、アスパラギン酸、アスパラギン酸塩、アミノエチルスルホン酸
本発明の眼科用組成物は液体が好ましく、20℃における粘度は、1~400mPa・sが好ましく、1~100mPa・sがより好ましく、1~60mPa・sがさらに好ましく、1~30mPa・sが特に好ましい。なお、粘度の測定方法はB型粘度計を用いて測定する。
本発明は、眼科用組成物と、この眼科用組成物が充填された容器と、この容器を包装する包囲体とを有する眼科用製品であって、眼科用組成物中の酸素濃度が低減された状態で保存される手段を用いて、上記(A),(B)成分を併用することによる粘度低下をより抑制することができる。手段としては、(1)包囲体内への不活性ガス注入、(2)包囲体内への酸素吸収剤の同梱、(3)酸素吸収能を有する容器又は(4)酸素吸収能を有する包囲体等が挙げられる。このような手段により、上記(A),(B)成分を併用することによる粘度低下をより抑制することができる。なお、包囲体は容器を密封できるものが好ましい。
不活性ガスとしては、窒素、ヘリウム、ネオン、アルゴン等が挙げられる。中でも窒素ガスが好ましい。不活性ガスの濃度は、包囲体とプラスチック製容器との間に形成された空間容積中、好ましくは50容積%以上、より好ましくは80容積%%以上、さらに好ましくは90容積%以上である。上限は特に限定されず、100容積%以下である。このような濃度にするためには、包囲体とプラスチック製容器との間に形成された空間を、不活性ガスで置換すればよい。
具体的には、三菱ガス化学(株)製のエージレス(登録商標)(FX、SP、SS、SPE、ZP、Z-PT、Z-PKC、GLS、GL-M、Z-20PKヤ)、ファーマキープ、(株)常盤産業製のバイタロン、(株)博洋製のサンソレス、パウダーテック(株)製のワンダーキープ、アイリス・ファインプロダクツ(株)製のサンソカット等を用いることができる。
具体的には、東洋製罐(株)製のオキシブロック、三菱ガス化学(株)製のオキシヴァニッシュ等を用いることができる。
具体的には、共同印刷(株)製のオキシキャッチ(登録商標)ICA、シールドエアー社製のCryovac(登録商標) OSフィルム、スタープラスチック工業(株)製のハイスターO2、三菱ガス化学(株)製のエージレスオーマック、東洋製罐(株)製のオキシデック等を用いることができる。
(B)ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油及びモノステアリン酸ポリエチレングリコールから選ばれる1種又は2種以上の界面活性剤、
(C)ビタミンA、ビタミンE、ジブチルヒドロキシトルエン及び清涼化剤から選ばれる1種以上の脂溶性成分を含有する眼科用組成物と、この眼科用組成物が充填された容器と、この容器を包装する包囲体とを有し、(1)包囲体内への不活性ガス注入、(2)包囲体内への酸素吸収剤の同梱、(3)酸素吸収能を有する容器又は(4)酸素吸収能を有する包囲体のいずれか1以上の手段を用いた眼科用製品において、上記眼科用組成物に、
(D)下記(D-1)及び(D-2)
(D-1)トロメタモール、プロピレングリコール
(D-2)エチレンジアミン酢酸誘導体、エチレンジアミン酢酸誘導体塩、塩酸テトラヒドロゾリン、イプシロンアミノカプロン酸、アラントイン、グリチルリチン酸、グリチルリチン酸塩、クロルフェニラミンマレイン酸塩、ピリドキシン塩酸塩、パンテノール、コンドロイチン硫酸、コンドロイチン硫酸塩、塩化ナトリウム、ネオスチグミンメチル硫酸塩、硫酸亜鉛、フラビンアデニンジヌクレオチドナトリウム、シアノコバラミン、アスパラギン酸、アスパラギン酸塩、アミノエチルスルホン酸
からなる群から選ばれる1種以上を配合することを特徴とする、眼科用組成物の粘度低下抑制方法を提供する。好適なもの、量等は上記と同様である。
(B)ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油及びモノステアリン酸ポリエチレングリコールから選ばれる1種又は2種以上の界面活性剤、
(C)ビタミンA、ビタミンE、ジブチルヒドロキシトルエン及び清涼化剤から選ばれる1種以上の脂溶性成分を含有する眼科用組成物において、
この眼科用組成物が充填された容器と、この容器を包装する包囲体とを有し、(1)包囲体内への不活性ガス注入、(2)包囲体内への酸素吸収剤の同梱、(3)酸素吸収能を有する容器又は(4)酸素吸収能を有する包囲体のいずれか1以上の手段を用いると共に、上記眼科用組成物に、
(D)下記(D-1)及び(D-2)
(D-1)トロメタモール、プロピレングリコール
(D-2)エチレンジアミン酢酸誘導体、エチレンジアミン酢酸誘導体塩、塩酸テトラヒドロゾリン、イプシロンアミノカプロン酸、アラントイン、グリチルリチン酸、グリチルリチン酸塩、クロルフェニラミンマレイン酸塩、ピリドキシン塩酸塩、パンテノール、コンドロイチン硫酸、コンドロイチン硫酸塩、塩化ナトリウム、ネオスチグミンメチル硫酸塩、硫酸亜鉛、フラビンアデニンジヌクレオチドナトリウム、シアノコバラミン、アスパラギン酸、アスパラギン酸塩、アミノエチルスルホン酸
からなる群から選ばれる1種以上を配合することを特徴とする、上記眼科用組成物の粘度低下抑制方法を提供する。好適なもの、量等は上記と同様である。
下記表に示す組成の眼科用組成物を、脂溶性成分を(B)成分に溶解した後、他の水溶液成分を溶解した高温(70~95℃)の水溶液に投入することによって下記表に示す組成の眼科用組成物を製造した。得られた眼科用組成物(15mL)をポリエチレンテレフタレート製の点眼剤容器(16mL)に充填した後、酸素吸収剤(エージレス:Z-20PKヤ 三菱ガス化学株式会社製)を同梱したフィルム包装(包囲体)を施した。また、比較例4及び実施例4-1~4-4、ならびに、比較例6及び実施例6-1~6-3については、酸素吸収能を有するフィルム(エージレスオーマック:三菱ガス化学株式会社製)を用いて包装(包囲体)を施した。なお、包囲体の酸素透過係数は10cc/m2・24hr・atm以下である。保存前の粘度をB型粘度計(デジタル粘度計DV2T、英弘精機株式会社製)にて粘度を測定し、50℃・75%RH環境下で2ケ月保存した。保存後、点眼剤を常温(20℃)に戻し、保存前と同様に測定した。得られた粘度から下記式に基づき、各実施例の粘度維持率(%)を求め、以下のように、粘度維持率増強効果(%)を算出した。
粘度維持率(%)=保存後の粘度/保存前の粘度×100
粘度維持率増強効果(%)=[各実施例の粘度維持率(%)/各実施例に対応する比較例の粘度維持率(%)-1]×100
なお、各実施例に対応する比較例とは、(D)成分を含まない比較例をいう。
下記表に示す組成の眼科用組成物を、本発明記載の容器に充填し、本発明記載の包装形態で包装した眼科用製品は、経時による粘度低下が抑制され、有効性や清涼感の持続性に優れ、また、うるおい感の持続性に優れた点眼剤として使用できる。特に、処方例3、5、10~12は、ソフトコンタクトレンズ装用時にも点眼可能なコンタクト用点眼剤として好適である。
・ヒドロキシプロピルメチルセルロース:メトローズ60SH-4000、日局、信越化学工業(株)、重量平均分子量約30万(g/mol)
・メチルセルロース:メトローズSM-4000、日局、信越化学工業(株)、重量平均分子量約36万(g/mol)
・ヒドロキシエチルセルロース:HEC-CF-V、薬添規、住友精化(株)、重量平均分子量約100万(g/mol)
・ポリビニルピロリドン:コリドン90F、日局、BASF(株)、重量平均分子量100万(g/mol)
カルボキシビニルポリマー:Carbopol(登録商標)971PNF、薬添規、ルーブリゾール社
・ヒアルロン酸ナトリウム:バイオヒアルロン酸ナトリウム、資生堂(株)
・ポリオキシエチレン硬化ヒマシ油60:HCO60、薬添規、日本サーファクタント工業(株)
・モノオレイン酸POE(20)ソルビタン(ポリソルベート80):レオドールTW-0120V、花王(株)
・ポリオキシエチレンヒマシ油35:NIKKOL CO-35、日光ケミカルズ(株)
・ステアリン酸ポリオキシル40:NIKKOL MYS-40MV、日光ケミカルズ(株)
・レチノールパルミチン酸エステル:レチノールパルミチン酸エステル、日局、DSMニュートリション ジャパン(株)
・酢酸d-α-トコフェロール:理研Eアセテートα、局外規、理研ビタミン(株)
・ジブチルヒドロキシトルエン:ジブチルヒドロキシトルエン、薬添規、和光純薬工業(株)
(D)成分及びその他の任意成分は、公定書(日本薬局方、日本薬局方外医薬品規格、医薬品添加物規格、等)規格に適合した各種原料を使用した。
Claims (6)
- (A)水溶性高分子化合物、
(B)ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油及びモノステアリン酸ポリエチレングリコールから選ばれる1種又は2種以上の界面活性剤、
(C)ビタミンA、ビタミンE、ジブチルヒドロキシトルエン及び清涼化剤から選ばれる1種以上の成分、及び
(D)下記(D-1)及び(D-2)からなる群から選ばれる1種以上
(D-1)トロメタモール、プロピレングリコール
(D-2)エチレンジアミン酢酸誘導体、エチレンジアミン酢酸誘導体塩、塩酸テトラヒドロゾリン、イプシロンアミノカプロン酸、アラントイン、グリチルリチン酸、グリチルリチン酸塩、クロルフェニラミンマレイン酸塩、ピリドキシン塩酸塩、パンテノール、コンドロイチン硫酸、コンドロイチン硫酸塩、塩化ナトリウム、ネオスチグミンメチル硫酸塩、硫酸亜鉛、フラビンアデニンジヌクレオチドナトリウム、シアノコバラミン、アスパラギン酸、アスパラギン酸塩、アミノエチルスルホン酸
を含有する眼科用組成物と、この眼科用組成物が充填された容器と、この容器を包装する包囲体とを有する眼科用製品であって、
(1)包囲体内への不活性ガス注入、(2)包囲体内への酸素吸収剤の同梱、(3)酸素吸収能を有する容器又は(4)酸素吸収能を有する包囲体のいずれか1以上の手段を用いた眼科用製品。 - (D)成分が、(D-1)群から1種以上及び(D-2)群から1種以上である請求項1記載の眼科用製品。
- (A)成分が、ヒドロキシプロピルメチルセルロース、メチルセルロース、ヒドロキシエチルセルロース、ポリビニルピロリドン、ポリビニルアルコール、カルボキシビニルポリマー、ヒアルロン酸及びその塩から選ばれる1種以上である請求項1又は2記載の眼科用製品。
- (C)成分が、レチノールパルミチン酸エステル、酢酸d-α-トコフェロール、ジブチルヒドロキシトルエン及びメントールから選ばれる1種以上である請求項1~3のいずれか1項記載の眼科用製品。
- (A)水溶性高分子化合物、
(B)ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油及びモノステアリン酸ポリエチレングリコールから選ばれる1種又は2種以上の界面活性剤、
(C)ビタミンA、ビタミンE、ジブチルヒドロキシトルエン及び清涼化剤から選ばれる1種以上の脂溶性成分を含有する眼科用組成物と、この眼科用組成物が充填された容器と、この容器を包装する包囲体とを有し、(1)包囲体内への不活性ガス注入、(2)包囲体内への酸素吸収剤の同梱、(3)酸素吸収能を有する容器又は(4)酸素吸収能を有する包囲体のいずれか1以上の手段を用いた眼科用製品において、上記眼科用組成物に、
(D)下記(D-1)及び(D-2)
(D-1)トロメタモール、プロピレングリコール
(D-2)エチレンジアミン酢酸誘導体、エチレンジアミン酢酸誘導体塩、塩酸テトラヒドロゾリン、イプシロンアミノカプロン酸、アラントイン、グリチルリチン酸、グリチルリチン酸塩、クロルフェニラミンマレイン酸塩、ピリドキシン塩酸塩、パンテノール、コンドロイチン硫酸、コンドロイチン硫酸塩、塩化ナトリウム、ネオスチグミンメチル硫酸塩、硫酸亜鉛、フラビンアデニンジヌクレオチドナトリウム、シアノコバラミン、アスパラギン酸、アスパラギン酸塩、アミノエチルスルホン酸
からなる群から選ばれる1種以上を配合することを特徴とする、上記眼科用組成物の粘度低下抑制方法。 - (A)水溶性高分子化合物、
(B)ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油及びモノステアリン酸ポリエチレングリコールから選ばれる1種又は2種以上の界面活性剤、
(C)ビタミンA、ビタミンE、ジブチルヒドロキシトルエン及び清涼化剤から選ばれる1種以上の脂溶性成分を含有する眼科用組成物において、
この眼科用組成物が充填された容器と、この容器を包装する包囲体とを有し、(1)包囲体内への不活性ガス注入、(2)包囲体内への酸素吸収剤の同梱、(3)酸素吸収能を有する容器又は(4)酸素吸収能を有する包囲体のいずれか1以上の手段を用いると共に、上記眼科用組成物に、
(D)下記(D-1)及び(D-2)
(D-1)トロメタモール、プロピレングリコール
(D-2)エチレンジアミン酢酸誘導体、エチレンジアミン酢酸誘導体塩、塩酸テトラヒドロゾリン、イプシロンアミノカプロン酸、アラントイン、グリチルリチン酸、グリチルリチン酸塩、クロルフェニラミンマレイン酸塩、ピリドキシン塩酸塩、パンテノール、コンドロイチン硫酸、コンドロイチン硫酸塩、塩化ナトリウム、ネオスチグミンメチル硫酸塩、硫酸亜鉛、フラビンアデニンジヌクレオチドナトリウム、シアノコバラミン、アスパラギン酸、アスパラギン酸塩、アミノエチルスルホン酸
からなる群から選ばれる1種以上を配合することを特徴とする、上記眼科用組成物の粘度低下抑制方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020197002869A KR20190065237A (ko) | 2016-10-07 | 2017-10-05 | 안과용 제품 및 점도 저하 억제 방법 |
JP2018543965A JP7120018B2 (ja) | 2016-10-07 | 2017-10-05 | 眼科用製品及び粘度低下抑制方法 |
JP2022093619A JP2022111328A (ja) | 2016-10-07 | 2022-06-09 | 眼科用製品及び粘度低下抑制方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-199036 | 2016-10-07 | ||
JP2016199036 | 2016-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018066651A1 true WO2018066651A1 (ja) | 2018-04-12 |
Family
ID=61831491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/036293 WO2018066651A1 (ja) | 2016-10-07 | 2017-10-05 | 眼科用製品及び粘度低下抑制方法 |
Country Status (4)
Country | Link |
---|---|
JP (2) | JP7120018B2 (ja) |
KR (1) | KR20190065237A (ja) |
TW (1) | TWI746662B (ja) |
WO (1) | WO2018066651A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019065008A (ja) * | 2017-10-04 | 2019-04-25 | ライオン株式会社 | 眼科用組成物及びその製造方法、ならびに吸着抑制方法 |
JP2019214560A (ja) * | 2018-06-08 | 2019-12-19 | ロート製薬株式会社 | 洗眼剤組成物 |
WO2020016732A1 (en) * | 2018-07-18 | 2020-01-23 | Farmigea S.P.A. | Composition comprising glycyrrhin and cosmetic and pharmaceutical uses thereof |
JP2020196672A (ja) * | 2019-05-31 | 2020-12-10 | 小林製薬株式会社 | ビタミンb12類含有組成物 |
US20210393609A1 (en) * | 2018-09-25 | 2021-12-23 | Shenyang Xingqi Pharmaceutical Co., Ltd. | Method for improving stability of low-concentration atropine ophthalmic preparation |
WO2022138143A1 (ja) * | 2020-12-23 | 2022-06-30 | 小林製薬株式会社 | 洗眼用組成物 |
RU2810709C2 (ru) * | 2018-05-31 | 2023-12-28 | Сэндзю Фармасьютикал Ко., Лтд. | Жидкое офтальмологическое средство с подавлением снижения содержания дибутилгидрокситолуола |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013183778A1 (ja) * | 2012-06-08 | 2013-12-12 | ライオン株式会社 | 粘膜用組成物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10193490A (ja) * | 1997-01-06 | 1998-07-28 | Mitsubishi Gas Chem Co Inc | 水性液状物質の包装方法 |
JPH1171478A (ja) | 1997-08-29 | 1999-03-16 | Santen Pharmaceut Co Ltd | 粘度低下防止方法 |
JP2003113078A (ja) * | 2001-09-28 | 2003-04-18 | Lion Corp | 眼科用製剤 |
JP2004123634A (ja) * | 2002-10-03 | 2004-04-22 | Lion Corp | 眼科用組成物 |
JP5382972B2 (ja) | 2003-12-26 | 2014-01-08 | ロート製薬株式会社 | 粘度低下が防止された組成物 |
JP5382973B2 (ja) | 2003-12-26 | 2014-01-08 | ロート製薬株式会社 | 粘度低下が防止された組成物 |
JP2006187636A (ja) * | 2006-02-01 | 2006-07-20 | Terumo Corp | ビタミンb1類含有水性製剤の安定化方法 |
JP2011021002A (ja) * | 2009-06-16 | 2011-02-03 | Lion Corp | 眼科用組成物 |
US9119827B2 (en) * | 2009-06-30 | 2015-09-01 | Lion Corporation | Ophthalmic composition |
JP2013237638A (ja) * | 2012-05-15 | 2013-11-28 | Lion Corp | 眼科組成物 |
JP6260230B2 (ja) * | 2013-11-28 | 2018-01-17 | ライオン株式会社 | 眼科用組成物 |
CN104127377A (zh) * | 2014-08-04 | 2014-11-05 | 珠海亿胜生物制药有限公司 | 一种不含抑菌剂的双氯芬酸钠滴眼液及其制备方法 |
-
2017
- 2017-10-05 JP JP2018543965A patent/JP7120018B2/ja active Active
- 2017-10-05 WO PCT/JP2017/036293 patent/WO2018066651A1/ja active Application Filing
- 2017-10-05 KR KR1020197002869A patent/KR20190065237A/ko not_active Application Discontinuation
- 2017-10-06 TW TW106134476A patent/TWI746662B/zh active
-
2022
- 2022-06-09 JP JP2022093619A patent/JP2022111328A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013183778A1 (ja) * | 2012-06-08 | 2013-12-12 | ライオン株式会社 | 粘膜用組成物 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019065008A (ja) * | 2017-10-04 | 2019-04-25 | ライオン株式会社 | 眼科用組成物及びその製造方法、ならびに吸着抑制方法 |
JP7310113B2 (ja) | 2017-10-04 | 2023-07-19 | ライオン株式会社 | 眼科用組成物及びその製造方法、ならびに吸着抑制方法 |
RU2810709C2 (ru) * | 2018-05-31 | 2023-12-28 | Сэндзю Фармасьютикал Ко., Лтд. | Жидкое офтальмологическое средство с подавлением снижения содержания дибутилгидрокситолуола |
JP2019214560A (ja) * | 2018-06-08 | 2019-12-19 | ロート製薬株式会社 | 洗眼剤組成物 |
WO2020016732A1 (en) * | 2018-07-18 | 2020-01-23 | Farmigea S.P.A. | Composition comprising glycyrrhin and cosmetic and pharmaceutical uses thereof |
IL280109B1 (en) * | 2018-07-18 | 2024-04-01 | Atg 20 S R L | Preparations containing glycyrrhizin and their cosmetic and medical uses |
CN112423723A (zh) * | 2018-07-18 | 2021-02-26 | 阿特戈20有限责任公司 | 包含甘草甜素的组合物及其美容和制药用途 |
JP2021530521A (ja) * | 2018-07-18 | 2021-11-11 | エーティージー 20 エス.アール.エル | グリチルリチンを含む組成物およびその化粧品および医薬品使用 |
CN112423723B (zh) * | 2018-07-18 | 2024-03-08 | 阿特戈20有限责任公司 | 包含甘草甜素的组合物及其美容和制药用途 |
US11406658B2 (en) | 2018-07-18 | 2022-08-09 | Atg 20 S.R.L. | Composition comprising glycyrrhizin and cosmetic and pharmaceutical uses thereof |
US20210393609A1 (en) * | 2018-09-25 | 2021-12-23 | Shenyang Xingqi Pharmaceutical Co., Ltd. | Method for improving stability of low-concentration atropine ophthalmic preparation |
JP2020196672A (ja) * | 2019-05-31 | 2020-12-10 | 小林製薬株式会社 | ビタミンb12類含有組成物 |
WO2022138143A1 (ja) * | 2020-12-23 | 2022-06-30 | 小林製薬株式会社 | 洗眼用組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP2022111328A (ja) | 2022-07-29 |
TW201813669A (zh) | 2018-04-16 |
JP7120018B2 (ja) | 2022-08-17 |
JPWO2018066651A1 (ja) | 2019-08-08 |
TWI746662B (zh) | 2021-11-21 |
KR20190065237A (ko) | 2019-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7120018B2 (ja) | 眼科用製品及び粘度低下抑制方法 | |
JP5549669B2 (ja) | 眼科用組成物、ドライアイ治療剤及びビタミンaの安定化方法 | |
JP7355539B2 (ja) | 眼科組成物 | |
JP7314986B2 (ja) | 眼科用製品及び粘度低下抑制方法 | |
KR101858590B1 (ko) | 안과용 조성물 | |
JP2011021002A (ja) | 眼科用組成物 | |
JP2005154437A (ja) | トラニラスト含有医薬組成物 | |
JP5729109B2 (ja) | ソフトコンタクトレンズ用眼科組成物 | |
JP2024061871A (ja) | 眼科組成物 | |
JP2005343894A (ja) | 抗菌点眼剤 | |
JP2023126377A (ja) | 眼科組成物 | |
JP2010204597A (ja) | ソフトコンタクトレンズ用組成物及びソフトコンタクトレンズへの吸着抑制方法 | |
WO2018225729A1 (ja) | ソフトコンタクトレンズ用眼科用組成物及びビタミンa分離抑制方法 | |
JP5083502B2 (ja) | 眼科用組成物 | |
KR102665052B1 (ko) | 안과용 제품 및 점도 저하 억제 방법 | |
JP7380772B2 (ja) | 眼科用製品及びマスキング方法 | |
JP2019189607A (ja) | 眼科組成物 | |
JP7379913B2 (ja) | ソフトコンタクトレンズ用眼科組成物及び眼科用製品 | |
JP2009079032A (ja) | 眼科用組成物及びジフェンヒドラミンの安定化方法 | |
JP2024059971A (ja) | 洗眼剤組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17858487 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20197002869 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018543965 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17858487 Country of ref document: EP Kind code of ref document: A1 |